Barrett esophagus: Understanding Your Pathology Report

by Jason Wasserman MD PhD FRCPC
July 29, 2026

Barrett esophagus is a change in the lining of the lower esophagus, the muscular tube that carries food and liquid from the mouth to the stomach. The esophagus is normally lined by squamous cells, flat, tough cells built to withstand the wear of swallowing. In Barrett esophagus, these are replaced by glandular cells of the kind normally found in the stomach and intestine. A change of one cell type into another is called metaplasia, and when the replacement cells resemble those of the intestine, the change is called intestinal metaplasia.

Barrett esophagus is not cancer. It is considered a precancerous condition because it raises the risk of developing adenocarcinoma of the esophagus. That risk is real but small: the large majority of people with Barrett esophagus never develop cancer. The reason the diagnosis matters is that it identifies people who can be watched over time, so that any further change can be found and treated at a stage when it is highly curable.

This article will help you understand the findings in your pathology report, what each term means, and why it matters for your care.

What causes Barrett esophagus?

Barrett esophagus is caused by years of injury to the lining of the lower esophagus, most often from gastroesophageal reflux disease (GERD). In GERD, stomach acid and bile flow backward into the esophagus repeatedly. The squamous cells that normally line the esophagus are not built to withstand this, and over time the lining is replaced by glandular cells, which tolerate acid better. Barrett esophagus can be thought of as the esophagus adapting to a hostile environment, at the cost of becoming more vulnerable to cancer.

GERD is by far the strongest risk factor, and Barrett esophagus is found in roughly 5% to 15% of people with long-standing reflux symptoms. Most people with GERD never develop it, however, and some people with Barrett esophagus have never had noticeable heartburn at all. Other factors that raise the risk include:

Long-standing reflux — Particularly symptoms present for more than 5 to 10 years.
Male sex — Barrett esophagus is roughly twice as common in men as in women.
Age over 50 — Risk rises with age.
Central obesity — Weight carried around the abdomen matters more than overall body weight, because it increases pressure that pushes stomach contents upward.
Smoking — A history of smoking increases risk, whether or not the person still smokes.
Family history — Having a first-degree relative with Barrett esophagus or esophageal adenocarcinoma raises risk.
White European ancestry — Barrett esophagus is more common in this group than in others.

Nothing about the way you have lived causes Barrett esophagus on its own, and the condition is not contagious. Treating reflux protects the lining from further damage, but it does not make an established Barrett segment disappear.

What are the symptoms of Barrett esophagus?

Barrett esophagus itself causes no symptoms. The changed lining does not hurt, bleed, or interfere with swallowing. Most people who are found to have it were having an endoscopy for another reason, usually to investigate reflux.

The symptoms people notice come from the underlying GERD rather than from Barrett esophagus. These include frequent heartburn, regurgitation of sour-tasting fluid or food, chest discomfort, and a sensation of food sticking. Because Barrett esophagus produces no symptoms of its own, changes in how you feel are not a reliable way to tell whether it is stable or progressing, which is why periodic endoscopy is used instead. Symptoms that are new or worsening, particularly difficulty swallowing or unexplained weight loss, should be reported promptly, since these can signal something more than reflux.

How is the diagnosis made?

Barrett esophagus is diagnosed by combining what the doctor sees during an endoscopy with what the pathologist sees under the microscope. Neither alone is enough, and this is why your report may refer to both.

During an upper endoscopy, a thin flexible tube with a camera is passed through the mouth into the esophagus. The normal esophageal lining is pale pink; Barrett esophagus appears as salmon-colored or reddish tongues or a continuous band extending upward from the stomach. For the diagnosis to be made in North America, this abnormal-looking lining must extend at least 1 cm above the top of the stomach folds. The doctor then takes small tissue samples, called biopsies, using a standard pattern: four samples taken around the circumference of the esophagus at every 1 to 2 cm along the abnormal segment, plus extra samples from any area that looks different from the rest.

Under the microscope, the pathologist looks for goblet cells, rounded mucus-producing cells normally found in the intestine. They are larger than the cells around them and are filled with mucin, which appears blue or purple on a routine stain. Goblet cells confirm intestinal metaplasia, and their presence alongside the endoscopic appearance establishes the diagnosis of Barrett esophagus. The pathologist then examines the tissue for any sign of dysplasia, described in a section below.

Two situations often cause confusion on a report. The first is when biopsies show intestinal metaplasia but the abnormal lining measured less than 1 cm, an appearance sometimes called an irregular Z-line. In North America, this is reported as intestinal metaplasia of the gastroesophageal junction rather than Barrett esophagus, because studies have found essentially no progression to cancer in this group, and surveillance is generally not recommended. The second is when the endoscopy looks like Barrett esophagus but the biopsies show columnar mucosa without goblet cells. Guidelines in the United States and Canada require goblet cells for the diagnosis, while guidelines in the United Kingdom and Japan do not, so a report may describe the finding without applying the label. If your report seems to describe Barrett esophagus without naming it, this difference in definitions is usually the reason, and it is worth asking your doctor which standard was applied.

Length of the Barrett segment

The length of the Barrett esophagus segment is measured during endoscopy and is one of the findings used in deciding how often the esophagus is examined again. Longer segments carry a somewhat higher risk of progressing to cancer than short ones, simply because more abnormal lining is present.

The measurement is usually reported using the Prague classification, which gives two numbers in centimeters:

C (circumferential extent) — The length of the segment where the abnormal lining forms a complete ring all the way around the inside of the esophagus.
M (maximal extent) — The distance from the top of the stomach folds to the highest point reached by any tongue of abnormal lining, even a narrow one.

A report reading C2M4, for example, describes a segment in which the abnormal lining forms a complete ring for 2 cm and extends as a tongue up to 4 cm. Segments shorter than 3 cm are described as short-segment Barrett esophagus and those 3 cm or longer as long-segment Barrett esophagus. This measurement is made by the endoscopist and appears on the endoscopy report; the pathologist does not measure it, so it may not appear on the pathology report itself.

Dysplasia

Dysplasia means that the glandular cells in the Barrett segment have started to look abnormal under the microscope, with enlarged and darker nuclei, crowding, and loss of their orderly arrangement. It is the single most important thing the pathologist looks for in a Barrett biopsy, because it marks a step along the path toward cancer and because it is the finding that determines what happens next. Every Barrett biopsy report will state which of the following categories applies:

Negative for dysplasia — The glandular cells look the way they should in Barrett esophagus, with no abnormal features. This is the most common and most reassuring result, and it means your report shows Barrett esophagus alone.
Indefinite for dysplasia — The cells look abnormal, but the pathologist cannot tell whether this reflects true dysplasia or a reaction to inflammation, an ulcer, or recent injury, all of which can make cells look worrying without being precancerous. This is not a diagnosis of dysplasia and it is not a diagnosis of cancer; it means the answer is genuinely uncertain on this sample. It is usually resolved by treating the reflux intensively for a few months and then repeating the biopsies, at which point most cases show no dysplasia.
Low grade dysplasia — The cells show clear but limited abnormality. The abnormal cells are confined to the surface and the glands beneath, and the risk of progressing to cancer is higher than in Barrett esophagus without dysplasia, though still modest.
High grade dysplasia — The cells look markedly abnormal and disorganized, approaching the appearance of cancer, but they have not broken out of the glands into the surrounding tissue. This carries the highest risk of progression and is the finding that most often leads to treatment.
Adenocarcinoma — Cancer cells have broken out of the glands and are growing into the tissue beneath. When this growth is still confined to the innermost layer, it is called intramucosal carcinoma, an early and usually curable stage.

Grading dysplasia is one of the more difficult judgments in pathology, and pathologists reviewing the same slides do not always agree, particularly at the boundary between reactive change, indefinite, and low grade dysplasia. Because the diagnosis carries real consequences, guidelines recommend that any diagnosis of dysplasia be confirmed by a second pathologist with expertise in gastrointestinal pathology before treatment is planned. It is common for a diagnosis of low grade dysplasia to be revised to no dysplasia on that review, and a revised diagnosis is not an error but the system working as intended.

p53 immunohistochemistry

p53 is a protein that normally helps a cell repair damaged DNA or, when the damage is too great, shut itself down. The gene that makes it is one of the earliest to be damaged as Barrett esophagus progresses toward cancer. Immunohistochemistry, a test that uses antibodies to detect proteins inside cells, can show whether the p53 protein is behaving normally. It is used as an aid when deciding whether abnormal-looking cells represent true dysplasia, and the result may appear on your report.

Normal (wild-type) pattern — Scattered cells show a small amount of p53, which is what healthy tissue looks like. This result argues against dysplasia and supports a reactive explanation for abnormal-looking cells.
Overexpression pattern — Strong staining in many cells in a row, caused by a damaged gene producing a protein the cell cannot clear. This supports a diagnosis of dysplasia.
Null pattern — Complete absence of staining in an area where surrounding normal cells do stain. This also reflects a damaged gene and supports dysplasia.

Both the overexpression and null patterns are described as abnormal or aberrant. p53 is a supporting test rather than a decisive one: an abnormal result does not by itself diagnose dysplasia, and a normal result does not by itself rule it out. British guidelines recommend adding p53 to the assessment of Barrett biopsies, while American guidelines have not yet endorsed it for predicting who will progress, so practice varies between centers. Not every Barrett biopsy is tested, and a report that does not mention p53 is not incomplete.

What is the risk that Barrett esophagus will become cancer?

The risk that Barrett esophagus will progress to adenocarcinoma of the esophagus depends almost entirely on whether dysplasia is present and, if so, at what grade. For most people, the risk is low, and it is worth keeping in perspective: the majority of people diagnosed with Barrett esophagus die of something else entirely.

Barrett esophagus without dysplasia — Roughly 0.3% of people per year progress to cancer, or about 1 in 300 each year. Most people in this group never progress at all.
Indefinite for dysplasia — The risk sits between that of no dysplasia and low grade dysplasia. Most cases are reclassified as no dysplasia once inflammation is treated and biopsies are repeated.
Low grade dysplasia — Roughly 0.7% per year in large series, though the figure is substantially higher in studies where the diagnosis was confirmed by expert pathologists, which is why confirmation matters so much.
High grade dysplasia — Roughly 6% to 7% per year without treatment, which is why treatment rather than watching is the usual course.

Other findings that raise the risk somewhat include a longer Barrett segment, an abnormal p53 result, and continued uncontrolled reflux. Ongoing smoking also increases risk. These factors modify the picture, but the dysplasia grade remains the dominant one.

What happens after this diagnosis?

Once Barrett esophagus has been diagnosed, the findings on the pathology report, particularly the dysplasia grade, together with the length of the segment, determine what the care team considers next. Two things run in parallel: controlling the reflux that caused the change in the first place, and monitoring or treating the Barrett segment itself.

Reflux control is part of care at every stage. Daily acid-suppressing medication, usually a proton pump inhibitor, is used both to relieve symptoms and because it appears to reduce the chance of progression. Weight loss where relevant, stopping smoking, avoiding late meals, and raising the head of the bed are commonly discussed alongside medication.

What happens to the Barrett segment depends on the report:

No dysplasia — Periodic surveillance endoscopy with repeat biopsies. Intervals are generally longer for short segments and shorter for long ones, commonly around every 5 years for segments under 3 cm and every 3 years for longer ones. No treatment of the Barrett lining itself is recommended, because the risk of progression is lower than the risk of the procedure.
Indefinite for dysplasia — Intensified acid suppression for a few months followed by repeat endoscopy and biopsies, so the tissue can be reassessed once inflammation has settled.
Low grade dysplasia — Confirmation by a second expert pathologist first. If dysplasia is confirmed, current guidelines favor endoscopic eradication therapy, most often radiofrequency ablation, which uses controlled heat to destroy the abnormal lining so healthy squamous lining can grow back. Randomized trials show this substantially lowers progression compared with watching alone. Surveillance every 12 months remains an accepted alternative, and the choice takes into account other health conditions and the person’s own preferences.
High grade dysplasia — Endoscopic eradication therapy is the standard approach. Any raised or visible area is first removed in one piece by endoscopic resection, both to treat it and to confirm no invasive cancer is hiding within it, and the remaining flat Barrett lining is then ablated. Surgery to remove part of the esophagus is now rarely needed for high grade dysplasia alone.

After successful eradication, endoscopy continues at intervals, because Barrett esophagus can return in a minority of people even after the lining appears fully replaced. For people who have never been screened, non-endoscopic tests using a swallowed sponge or capsule that collects cells from the esophagus are now available in some centers as an alternative first step for those with chronic reflux and other risk factors.

Questions to ask your doctor

Did my biopsy show dysplasia, and if so, what grade?
If my report says indefinite for dysplasia, what does that mean for me, and when should the biopsies be repeated?
Was my dysplasia diagnosis confirmed by a second pathologist with gastrointestinal expertise?
How long is my Barrett segment, and was it reported using the Prague classification?
Were goblet cells found in my biopsy, and does my diagnosis meet the full criteria for Barrett esophagus?
Was p53 testing performed on my biopsy, and what did it show?
Based on my report, what is my estimated risk of developing esophageal cancer?
How often should I have surveillance endoscopy, and how many biopsies should be taken each time?
Would endoscopic treatment be appropriate in my case, or is monitoring the better option?
What medication should I take for reflux, and will I need it long term?
What lifestyle changes would make the most difference for my reflux?
Should any of my family members be screened for Barrett esophagus?
What symptoms should prompt me to contact you before my next scheduled endoscopy?